Suppr超能文献

吲唑到 2-氰基吲哚结构的进展为分枝杆菌硫辛酰胺脱氢酶抑制剂实现了延长的靶标停留时间和提高的抗菌活性。

Indazole to 2-Cyanoindole Scaffold Progression for Mycobacterial Lipoamide Dehydrogenase Inhibitors Achieves Extended Target Residence Time and Improved Antibacterial Activity.

机构信息

Sanders Tri-Institutional Therapeutics Discovery Institute, Bronk Laboratory, 1230 York Avenue, Box 122, New York, NY 10065, USA.

Structural Biology Program, Sloan Kettering Institute, 1275 York Avenue, New York, NY 10065, USA.

出版信息

Angew Chem Int Ed Engl. 2024 Oct 24;63(44):e202407276. doi: 10.1002/anie.202407276. Epub 2024 Sep 20.

Abstract

Tuberculosis remains a leading cause of death from a single infection worldwide. Drug resistance to existing and even new antimycobacterials calls for research into novel targets and unexplored mechanisms of action. Recently we reported on the development of tight-binding inhibitors of Mycobacterium tuberculosis (Mtb) lipoamide dehydrogenase (Lpd), which selectively inhibit the bacterial but not the human enzyme based on a differential modality of inhibitor interaction with these targets. Here we report on the striking improvement in inhibitor residence time on the Mtb enzyme associated with scaffold progression from an indazole to 2-cyanoindole. Cryo-EM of Lpd with the bound 2-cyanoindole inhibitor 19 confirmed displacement of the buried water molecule deep in the binding channel with a cyano group. The ensuing hours-long improvement in on-target residence time is associated with enhanced antibacterial activity in axenic culture and in primary mouse macrophages. Resistance to 2-cyanoindole inhibitors involves mutations within the inhibitor binding site that have little effect on inhibitor affinity but change the modality of inhibitor-target interaction, resulting in fast dissociation from Lpd. These findings underscore that on-target residence time is a major determinant of antibacterial activity and in vivo efficacy.

摘要

结核病仍然是全球范围内单一感染导致死亡的主要原因。现有甚至新的抗分枝杆菌药物耐药性要求研究新的靶点和未探索的作用机制。最近,我们报告了结核分枝杆菌(Mtb)脂酰基辅酶 A 脱氢酶(Lpd)的紧密结合抑制剂的开发,这些抑制剂基于与这些靶标的抑制剂相互作用的不同模式,选择性地抑制细菌而不是人类酶。在这里,我们报告了与从吲唑到 2-氰基吲哚的支架进展相关的抑制剂在 Mtb 酶上的停留时间的惊人改善。与结合的 2-氰基吲哚抑制剂 19 的 Lpd 的冷冻电镜证实了埋藏在结合通道深处的水分子被氰基取代。随后,在无细胞培养物中和原代小鼠巨噬细胞中,靶标停留时间的长时间改善与增强的抗菌活性相关。对 2-氰基吲哚抑制剂的抗性涉及抑制剂结合位点内的突变,这些突变对抑制剂亲和力几乎没有影响,但改变了抑制剂-靶标相互作用的模式,导致与 Lpd 的快速解离。这些发现强调了靶标停留时间是抗菌活性和体内疗效的主要决定因素。

相似文献

本文引用的文献

7
BPaL approved for multidrug-resistant tuberculosis.BPaL方案被批准用于治疗耐多药结核病。
Lancet Infect Dis. 2019 Oct;19(10):1063-1064. doi: 10.1016/S1473-3099(19)30489-X.
8
Targeting drugs for tuberculosis.针对结核病的靶向药物。
Science. 2019 Jun 28;364(6447):1234-1235. doi: 10.1126/science.aay0211.
9
A survey of the role of nitrile groups in protein-ligand interactions.腈基在蛋白-配体相互作用中的作用研究综述。
Future Med Chem. 2018 Dec;10(23):2713-2728. doi: 10.4155/fmc-2018-0252. Epub 2018 Dec 6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验